Stacey Chu1, Nita Chen2, Alexis B C Dang3, Alfred C Kuo3, Alan B C Dang3. 1. 1Geisel School of Medicine at Dartmouth College, West Lebanon, NH. 2. Albany Medical College, School of Medicine, Albany NY. 3. University of California, San Francisco, Department of Orthopaedic Surgery, San Francisco, CA.
Abstract
BACKGROUND: The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). METHODS: Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. RESULTS: There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p<0.0001), 24.82% at 6400 μg/mL (p<0.0001) and 51.83% at 12800 μg/mL of vancomycin (p<0.0001) in comparison to the control group containing no vancomycin. CONCLUSIONS: Our in vitro study suggests that vancomycin has toxic effects on hMSCs, a cell population particularly important for bone formation. In the absence of any clinical evidence suggesting that "more vancomycin is better," and our data suggesting that more vancomycin is harmful in vitro, surgeons electing to use topical vancomycin in spine surgery should restrict their use to the doses currently reported in the available published studies unless specific reasons exist otherwise. This study does not establish a contraindication to the use of topical vancomycin, nor does it suggest that pseudarthroses are attributable to vancomycin use.
BACKGROUND: The use of topical vancomycin is increasingly popular in spine surgery. Large retrospective reviews suggest that topical vancomycin provides a cost-effective decrease in post-operative infection. Currently, there is little that is known about the maximum dose that can be applied locally. When 1 gram of vancomycin is mixed into the bone graft and another 1 gram applied freely in a spine wound, the local concentration of antibiotic ranges from 260-2900 μg/mL in the immediate post-op period and 50-730 μg/mL by the second post-operative day. We hypothesized that exuberant doses of vancomycin would be toxic to mesenchymal stem cells (MSCs). METHODS: Bone marrow was obtained from the femoral canal of patients undergoing routine elective total hip arthroplasty. Mesenchymal stem cells were isolated using plastic adhesion. Cells were exposed to a wide range of doses of vancomycin for 24 hours and then assessed for viability. Osteogenic potential was assessed with alizarin red staining. RESULTS: There was dose-dependent cell death with vancomycin use. MSC death was 9.43% at 400 μg/mL (p=0.047), 13.79% at 1600 μg/mL (p=0.0047), 19.35% at 3200 μg/mL (p<0.0001), 24.82% at 6400 μg/mL (p<0.0001) and 51.83% at 12800 μg/mL of vancomycin (p<0.0001) in comparison to the control group containing no vancomycin. CONCLUSIONS: Our in vitro study suggests that vancomycin has toxic effects on hMSCs, a cell population particularly important for bone formation. In the absence of any clinical evidence suggesting that "more vancomycin is better," and our data suggesting that more vancomycin is harmful in vitro, surgeons electing to use topical vancomycin in spine surgery should restrict their use to the doses currently reported in the available published studies unless specific reasons exist otherwise. This study does not establish a contraindication to the use of topical vancomycin, nor does it suggest that pseudarthroses are attributable to vancomycin use.
Authors: Joel R Martin; Owoicho Adogwa; Christopher R Brown; Carlos A Bagley; William J Richardson; Shivanand P Lad; Maragatha Kuchibhatla; Oren N Gottfried Journal: Spine (Phila Pa 1976) Date: 2014-01-15 Impact factor: 3.468
Authors: Justin S Smith; Christopher I Shaffrey; Charles A Sansur; Sigurd H Berven; Kai-Ming G Fu; Paul A Broadstone; Theodore J Choma; Michael J Goytan; Hilali H Noordeen; Dennis R Knapp; Robert A Hart; William F Donaldson; David W Polly; Joseph H Perra; Oheneba Boachie-Adjei Journal: Spine (Phila Pa 1976) Date: 2011-04-01 Impact factor: 3.468
Authors: Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers Journal: Clin Infect Dis Date: 2011-02-01 Impact factor: 9.079
Authors: Marco C Mendoza; Kevin A Sonn; Abhishek S Kannan; Sharath S Bellary; Sean M Mitchell; Gurmit Singh; Christian Park; Chawon Yun; Stuart R Stock; Erin L Hsu; Wellington K Hsu Journal: J Neurosurg Spine Date: 2016-04-01
Authors: Edward M Schwarz; Alex C McLaren; Thomas P Sculco; Barry Brause; Mathias Bostrom; Stephen L Kates; Javad Parvizi; Volker Alt; William V Arnold; Alberto Carli; Antonia F Chen; Hyonmin Choe; Débora C Coraça-Huber; Michael Cross; Michelle Ghert; Noreen Hickok; Jessica Amber Jennings; Manjari Joshi; Willem-Jan Metsemakers; Mark Ninomiya; Kohei Nishitani; Irvin Oh; Douglas Padgett; Benjamin Ricciardi; Kordo Saeed; Parham Sendi; Bryan Springer; Paul Stoodley; Joseph C Wenke Journal: J Orthop Res Date: 2020-03-02 Impact factor: 3.102
Authors: Willem-Jan Metsemakers; Austin T Fragomen; T Fintan Moriarty; Mario Morgenstern; Kenneth A Egol; Charalampos Zalavras; William T Obremskey; Michael Raschke; Martin A McNally Journal: J Orthop Trauma Date: 2020-01 Impact factor: 2.884